WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

The global Drug Discovery Services Market , valued at US$14.89 billion in 2024, is forecasted to grow at a robust CAGR of 10.7%, reaching US$16.36 ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the ...

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it ...

China health care companies received a significant reprieve in terms of geopolitical risks when the US Senate declined to ...

With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. | With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the ...

Trump threatened to enact 200% tariffs on all alcoholic products coming from the European Union in retaliation for the bloc’s ...

Contract research and manufacturing services firm Syngene International Ltd on Monday (March 10) announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...